Cancer Molecular Diagnostics: On The Critical Path To Personalized Medicine
The presentation will cover strategic insight into the U.S. cancer molecular diagnostics market and how the market correlates with growth in the world of personalized medicine. The briefing will examine the competitive dynamics of two main routes to get cancer molecular diagnostic tests to market - CLIA versus IVD models. It is crucial for any company or investor to examine the details of the rapid growth taking place in the fragmented space of the cancer molecular diagnostics market in order to exploit growth opportunities.
The briefing will benefit: clinical diagnostics companies and pharmaceutical companies, biotechnology companies, personalized medicine companies, companion diagnostics companies, investors and venture capital firms, life sciences research tools providers, platform technology providers, biomarker discovery companies, pharmacogenomics services providers, and contract research organizations. The briefing will highlight the critical questions that surround companion diagnostics and pharmacogenomicsyea.
"The regulatory environment around the cancer molecular diagnostics is still in flux," states Frost & Sullivan Senior Research Analyst Sudeep Basu, PhD. "While the near term benefit the adoption of a CLIA lab-based strategy are reaping, the long term view must be kept in perspective."
To participate, please email Stephanie Ochoa, Corporate Communications, at stephanie.ochoa@frost.com with the following information: your full name, title, company name, company telephone number, company e-mail address, city, state and country. Upon receipt of the above information, a registration link will be emailed to you. You may also register to receive a recorded version of the briefing at anytime by submitting the aforementioned contact details.
Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnerships, visit www.frost.com.
Cancer Molecular Diagnostics: Pe calea cãtre critici Personalizatã Medicina - Cancer Molecular Diagnostics: On The Critical Path To Personalized Medicine - articole medicale engleza - startsanatate